Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …

Understanding how metabolites are longitudinally influenced by age and sex could facilitate
the identification of metabolomic profiles and trajectories that indicate disease risk. We …

Major depressive disorder (MDD) is a debilitating psychiatric illness. However, there is
currently no objective laboratory-based diagnostic tests for this disorder. Although …

Alzheimer's disease (AD) is determined by various pathophysiological mechanisms starting
10–25 years before the onset of clinical symptoms. As multiple functionally interconnected …

Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD),
and amyotrophic lateral sclerosis (ALS) lack robust diagnostics and prognostic biomarkers …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that slowly destroys
memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 …

Background The panel of fluid-and imaging-based biomarkers available for
neurodegenerative disease research is growing and has the potential to close important …

Blood-based biomarkers represent a less invasive and potentially cheaper approach for
aiding Alzheimer's disease (AD) detection compared with cerebrospinal fluid and some …

An untargeted metabolomics study has been carried out using plasma samples from
patients with Mild Cognitive Impairment due to Alzheimer's disease patients (MCI-AD, n= 29) …